Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Рандомизированное исследование III фазы: сравнительная оценка комбинации капецитабина и оксалиплатина (XELOX) с комбинацией 5-фторурацила/лейковорина/ оксалиплатина (FOLFOX) в качестве первой линии терапии метастатического колоректального рака
Рандомизированное исследование III фазы: сравнительная оценка комбинации капецитабина и оксалиплатина (XELOX) с комбинацией 5-фторурацила/лейковорина/ оксалиплатина (FOLFOX) в качестве первой линии терапии метастатического колоректального рака
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938–47.
2. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 2001; 19: 4097–106.
3. Van Cutsem E, Hoff PM, Harper P et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: Integrated efficacy data and novel analyses from two large, randomized, phase III trials. Br J Cancer 2004; 90: 1190–7.
4. Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 2001; 19: 2282–92.
5. Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696–704.
6. Cassidy J, Tabernero J, Twelves C et al. XELOX (capecitabine plus oxaliplatin): Active firstline therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22: 2084–91.
7. Grothey A, Jordan K, Kellner O et al. Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC): Updated results of a randomized phase II trial. Eur J Cancer 2003; 1: S90 (suppl; abstr 295).
8. Scheithauer W, Kornek GV, Raderer M et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003; 21: 1307–12.
9. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–42.
10. Saltz L, Clarke S, Diaz-Rubio E et al. Efficacy and safety of bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol doi:10.1200/JCO.2007.14.9930
11. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205–16.
12. Ducreux M, Bennouna J, Hebbar M et al. Efficacy and safety findings from a randomized phase III study of capecitabine (X) + oxaliplatin (O) (XELOX) vs. infusional 5- FU/LV + O (FOLFOX-6) for metastatic colorectal cancer (MCRC). J Clin Oncol 2007; 25: 170s (suppl; abstr 4029).
13. Porschen R, Arkenau H-T, Kubicka S et al. Capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin: A randomized comparison in metastatic colorectal cancer – a final report of the AIO Colorectal Study Group. J Clin Oncol 2007; 25: 4217–23.
14. Diaz-Rubio E, Tabernero J, Gomez-Espana A et al. Phase III study of capecitabine plus oxaliplatin versus continuous infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: Final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors trial. J Clin Oncol 2007; 25: 4224–30.
15. Rothenberg ML, Navarro M, Butts C et al. Phase III trial of capecitabine + oxaliplatin (XELOX) vs. 5-fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (FOLFOX4) as 2nd-line treatment for patients with metastatic colorectal cancer (MCRC). J Clin Oncol 2007; 25: 171s (abstr 4031).
2. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study. J Clin Oncol 2001; 19: 4097–106.
3. Van Cutsem E, Hoff PM, Harper P et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: Integrated efficacy data and novel analyses from two large, randomized, phase III trials. Br J Cancer 2004; 90: 1190–7.
4. Hoff PM, Ansari R, Batist G et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study. J Clin Oncol 2001; 19: 2282–92.
5. Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696–704.
6. Cassidy J, Tabernero J, Twelves C et al. XELOX (capecitabine plus oxaliplatin): Active firstline therapy for patients with metastatic colorectal cancer. J Clin Oncol 2004; 22: 2084–91.
7. Grothey A, Jordan K, Kellner O et al. Capecitabine plus irinotecan (CAPIRI) vs capecitabine plus oxaliplatin (CAPOX) as first-line therapy of advanced colorectal cancer (ACRC): Updated results of a randomized phase II trial. Eur J Cancer 2003; 1: S90 (suppl; abstr 295).
8. Scheithauer W, Kornek GV, Raderer M et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2003; 21: 1307–12.
9. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335–42.
10. Saltz L, Clarke S, Diaz-Rubio E et al. Efficacy and safety of bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol doi:10.1200/JCO.2007.14.9930
11. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205–16.
12. Ducreux M, Bennouna J, Hebbar M et al. Efficacy and safety findings from a randomized phase III study of capecitabine (X) + oxaliplatin (O) (XELOX) vs. infusional 5- FU/LV + O (FOLFOX-6) for metastatic colorectal cancer (MCRC). J Clin Oncol 2007; 25: 170s (suppl; abstr 4029).
13. Porschen R, Arkenau H-T, Kubicka S et al. Capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin: A randomized comparison in metastatic colorectal cancer – a final report of the AIO Colorectal Study Group. J Clin Oncol 2007; 25: 4217–23.
14. Diaz-Rubio E, Tabernero J, Gomez-Espana A et al. Phase III study of capecitabine plus oxaliplatin versus continuous infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: Final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors trial. J Clin Oncol 2007; 25: 4224–30.
15. Rothenberg ML, Navarro M, Butts C et al. Phase III trial of capecitabine + oxaliplatin (XELOX) vs. 5-fluorouracil (5-FU), leucovorin (LV), and oxaliplatin (FOLFOX4) as 2nd-line treatment for patients with metastatic colorectal cancer (MCRC). J Clin Oncol 2007; 25: 171s (abstr 4031).
Авторы
________________________________________________
J Clin Oncol 2008; 26 (12): 2006–12
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.